CA-GIANT-PROTOCOL
GIANT Protocol, a leading-edge web3 protocol building a decentralized connectivity economy, today announced the release of its Litepaper, laying out the various components of GIANT Protocol’s ambitious proposal to decentralize and democratize access to the internet and financial services through a web3 telecommunications layer. GIANT plans to roll out the first iteration of its mainnet in the first half of 2022, so the publication of the Litepaper marks a critical step in ensuring GIANT Protocol’s commitment to being an open-source, public protocol built to support a globally connected world.
GIANT Protocol made its debut in November 2021, announcing its intention to build a tokenized bandwidth platform that will allow anyone with a mobile phone to access the internet and earn rewards based on their connectivity. With a founding team well-established in the telecom sector, GIANT Protocol intends to leverage existing network providers, allowing it to rapidly scale its network.
In December 2021, GIANT Protocol announced it had successfully raised $5 million in a seed funding round led by leading blockchain investment firm CoinFund. Now, the project is pleased to build on this progress with the publication of the Litepaper.
The Litepaper was co-authored by Suruchi Gupta, Founder, and CEO of Giant Protocol, along with the GIANT team. Speaking of its publication, Ms. Gupta commented: “The GIANT Litepaper lays out in detail the context and strategy for building a global telecommunications network that can deliver the benefits of web3 to everyone. We want it to convey our ultimate vision for GIANT: to make internet access more than a boring utility, transforming it into an exciting opportunity for better, faster, and more accessible internet access and accompanying financialization potential.”
Along with contextualizing the need for a global decentralized connectivity economy, the Litepaper provides an overview of GIANT’s proposal for its core connectivity infrastructure. It also outlines the GIANT tokenomic model and explains the DAO governance structure that will manage the protocol, including the role of the GIANT Protocol Foundation, a non-profit organization dedicated to supporting the protocol.
Finally, it shows what to expect from the first implementation of the GIANT Protocol – a wallet, a consumer software for end users to interact with GIANT, a provider software for network providers to offer internet access via GIANT, and a validator node software.
GIANT Protocol now invites feedback on the Litepaper from interested stakeholders who wish to be involved in the development and adoption of the GIANT Protocol, whether they’re network owners, developers, or data consumers.
To view the Litepaper, please visit https://giantprotocol.org/litepaper/
About GIANT Protocol
GIANT Protocol was founded in 2021 to decentralize and democratize access to the internet and financial services by tokenizing bandwidth. The project partners with telecommunications and connectivity providers across the globe to create a decentralized connectivity economy, allowing anyone with a mobile phone to participate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005732/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom